Medpace Holdings, Inc. (MEDP)
Medpace provides outsourced clinical trial services to drug, biologic and medical device developers. It last closed at $653.09 on Nov 17, up 0.75% on the day. MEDP reports earnings on Mon, Feb 8, 2027. The average 12-month price target from 6 analysts is $675.17 (+3.4% from the last close), with a high of $700.00 and a low of $633.00. Analyst consensus is Hold, based on the latest ratings from 6 firms (1 buy, 5 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in MEDP, 100% of them bullish and 0% bearish. In the past 30 days there were 3 dark pool prints totaling $3.2M, the largest $1.4M.
Key Stats
Last 12 monthsNot reported for this period.
From MEDP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 22). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on MEDP in the past 90 days. The average target is $675.17, with a high of $700.00 and a low of $633.00, compared with the last close of $653.09.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 26 | BMO Capital | Target raised | Hold | $600 → $670 |
| Oct 23 | UBS | Target raised | Hold | $673 → $700 |
| Oct 23 | Truist Securities | Target raised | Hold | $609 → $633 |
| Oct 23 | Barclays | Target raised | Hold | $625 → $675 |
| Oct 23 | TD Cowen | Target raised | Hold | $492 → $673 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 18% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the Pivot at $648.65, and the nearest resistance the Pivot R1 at $658.10.
| RSI (14) | 51.74 | Middle of its range | Neutral |
| MACD | 6.51 | Below its signal line | Bearish |
| Stochastic | 32.9 | Middle of its range | Neutral |
| ADX (14) | 28.6 | Trending up | |
| Williams %R | -63.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -86.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −1.6% | Change over 10 sessions | Bearish |
| ATR (14) | $19.39 | Typical daily range, 3.0% of price |
| RSI (14) | 64.41 | Strong, overbought above 70 | Neutral |
| MACD | 37.07 | Above its signal line | Bullish |
| Stochastic | 67.6 | Middle of its range | Neutral |
| ADX (14) | 41.2 | Strong uptrend | |
| Williams %R | -33.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 101.0 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +11.2% | Change over 10 sessions | Bullish |
| ATR (14) | $41.42 | Typical daily range, 6.3% of price |
What happened before
See how MEDP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MEDP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in MEDP in the last 90 days.
Dark Pool
30DMEDP Institutional Ownership
Full report →- ▲373 buying vs 316 selling
- ▼Held by funds -6.2 pts
- ▲Funds holding +53
- ▲Superinvestors: 5 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 755 | 702 | +7.5% |
| In funds' top 10 | 6 | 5 | +20.0% |
| Held by funds | 82.5% | 88.7% | −6.2 pts |
| New / increased | 127 / 246 | 67 / 206 | +36.6% |
| Reduced / sold out | 255 / 61 | 309 / 104 | −23.5% |
| Put/call ratio | 6.66 | 0.91 | +632.2% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MEDP is in one of them and how their past MEDP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MEDP in an article yet. Here's the latest on the wider market.
MEDP Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| David TaylorR · OH | Buy | $1K – $15K | May 15, 2026 | May 28, 2026 | 13 d |
| David TaylorR · OH | Buy | $1K – $15K | May 15, 2026 | May 28, 2026 | 13 d |
| Arjun ModyExecutive branch | Sell | $1K – $15K | Jan 30, 2026 | Apr 10, 2026 | 70 d |
| David TaylorR · OH | Buy | $1K – $15K | Feb 26, 2026 | Mar 6, 2026 | 8 d |
| Gilbert CisnerosD · CA | Sell | $15K – $50K | Jan 15, 2026 | Feb 13, 2026 | 29 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Medpace Holdings
Medpace is a contract research organization that runs clinical trials for drug, biologic and medical device developers. It provides services across the full clinical development process, from early Phase I testing through Phase IV, including study management, patient recruitment, monitoring, regulatory affairs, biometrics, safety reporting, and laboratory testing. Its customers include small, midsize and large biopharmaceutical and pharmaceutical companies. The company is based in Cincinnati, Ohio.
- Headquarters
- Cincinnati, OH










